Program
linsitinib
Also written as “OSI-906” and “Linsitinib”.
Its studies are mostly in Graves Ophthalmopathy · Carcinoma, Non-Small-Cell Lung · Ovarian Neoplasms · Adrenocortical Carcinoma · Carcinoma, Hepatocellular, led by 2 companies.
Drug pageLinsitinib: every studyAll 27 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharmaits history only | 100 open or running | phase 3since Jun 17, 2009 | Aug 7, 2007 | none ahead |
| Sling Therapeutics | 32 open or running | phase 3since Mar 2, 2022 | Mar 2, 2022 | Jun 30, 2028phase 3 · NCT07753603 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sling Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 2, 2022First study: phase 3 study in Graves OphthalmopathyFirst studyNCT05276063 · 90 enrolled · United States, Canada, Italy and more
- Oct 16, 2023Phase 3 study in Graves OphthalmopathyNCT06112340 · 75 planned · United States
- Aug 3, 2026Phase 3 study in Graves OphthalmopathyNCT07753603 · 130 planned · United States
Ahead
- Jun 30, 2028Primary completion: phase 3 study in Graves OphthalmopathyNCT07753603
TargetBeta
“An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) ”NCIt, by rule
“Insulin-like growth factor I receptor inhibitor; Insulin receptor inhibitor”ChEMBL 37, by rule
Studies
All 3 Sling Therapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07753603Graves Ophthalmopathy · United States | 3 | Recruiting | Jun 30, 2028 | 130 |
| NCT06112340Graves Ophthalmopathy · United States | 3 | Recruiting | Jun 2026 | 75 |
| NCT05276063Graves Ophthalmopathy · United States, Canada, Italy and more | 3 | Completed | Oct 15, 2024 | 90 |
How it is read
Names in the registry
- “OSI-906”, 9 entries
- “linsitinib”, 3 entries
- “Linsitinib”, 1 entry
Conditions, from the studies’ own filings
- Graves Ophthalmopathy, 3 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Ovarian Neoplasms, 2 studies
- Adrenocortical Carcinoma, 1 study
- Carcinoma, Hepatocellular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.